Multiple CNS Therapies Advancing

An advanced pipeline that’s closer to where you live than you might expect.

Synaptic Modulation
Neuroinflammation
Neurometabolism

cvn424

Parkinson's disease
(Adjunctive & monotherapy)

cvn766

Schizophrenia
(Negative and cognitive symptoms)

CVN293

ALS/Alzheimer's disease
(Disease modification)

CVN398

Parkinson's disease
(Disease modification)

Target-18

Parkinson's disease
(Disease modification)

Target-26

Alzheimer's disease
(
Disease modification)

Multiple Early Targets

discovery
Lead generation
INd enabling
Phase 1
phase 2
phase 3

The CVN424/GPR6 relationship uniquely limits collateral impact to surrounding genes.

45% Increase in OFF time efficacy and up to 150% reduction in common side effect compared to current treatment options.

Target:

GPR6 - an inverse agonist for parkinson’s disease

Study Focus:

GPR6 - an inverse agonist for parkinson’s disease

Highlight:

GPR6 - an inverse agonist for parkinson’s disease

Our approach differs radically from dopamine agonists currently being used and studied elsewhere to treat broad spectrum targets with highly undesirabl  e side effects.  CVN424 is an inverse agonist that targets GPR6, a novel gene we’ve identified using our NETSseq Platform.  GPR6 is highly selectively expressed in striatal medium spiny neurons only on the indirect pathway of the basal ganglia circuit. By targeting this essential mechanism Parkinson’s patients can experience significant improvements in disease “off time”, with significant reduction in adverse side effects compared to current dopaminergic treatment options.

Learn  more

The CVN424/GPR6 relationship uniquely limits collateral impact to surrounding genes.

45% Increase in OFF time efficacy and up to 150% reduction in common side effect compared to current treatment options.

Target:

GPR6 - an inverse agonist for parkinson’s disease

Study Focus:

GPR6 - an inverse agonist for parkinson’s disease

Highlight:

GPR6 - an inverse agonist for parkinson’s disease

Our approach differs radically from dopamine agonists currently being used and studied elsewhere to treat broad spectrum targets with highly undesirabl  e side effects.  CVN424 is an inverse agonist that targets GPR6, a novel gene we’ve identified using our NETSseq Platform.  GPR6 is highly selectively expressed in striatal medium spiny neurons only on the indirect pathway of the basal ganglia circuit. By targeting this essential mechanism Parkinson’s patients can experience significant improvements in disease “off time”, with significant reduction in adverse side effects compared to current dopaminergic treatment options.

Learn  more

The CVN424/GPR6 relationship uniquely limits collateral impact to surrounding genes.

45% Increase in OFF time efficacy and up to 150% reduction in common side effect compared to current treatment options.

Target:

GPR6 - an inverse agonist for parkinson’s disease

Study Focus:

GPR6 - an inverse agonist for parkinson’s disease

Highlight:

GPR6 - an inverse agonist for parkinson’s disease

Our approach differs radically from dopamine agonists currently being used and studied elsewhere to treat broad spectrum targets with highly undesirabl  e side effects.  CVN424 is an inverse agonist that targets GPR6, a novel gene we’ve identified using our NETSseq Platform.  GPR6 is highly selectively expressed in striatal medium spiny neurons only on the indirect pathway of the basal ganglia circuit. By targeting this essential mechanism Parkinson’s patients can experience significant improvements in disease “off time”, with significant reduction in adverse side effects compared to current dopaminergic treatment options.

Learn  more

The CVN424/GPR6 relationship uniquely limits collateral impact to surrounding genes.

45% Increase in OFF time efficacy and up to 150% reduction in common side effect compared to current treatment options.

Target:

GPR6 - an inverse agonist for parkinson’s disease

Study Focus:

GPR6 - an inverse agonist for parkinson’s disease

Highlight:

GPR6 - an inverse agonist for parkinson’s disease

Our approach differs radically from dopamine agonists currently being used and studied elsewhere to treat broad spectrum targets with highly undesirabl  e side effects.  CVN424 is an inverse agonist that targets GPR6, a novel gene we’ve identified using our NETSseq Platform.  GPR6 is highly selectively expressed in striatal medium spiny neurons only on the indirect pathway of the basal ganglia circuit. By targeting this essential mechanism Parkinson’s patients can experience significant improvements in disease “off time”, with significant reduction in adverse side effects compared to current dopaminergic treatment options.

Learn  more

The CVN424/GPR6 relationship uniquely limits collateral impact to surrounding genes.

45% Increase in OFF time efficacy and up to 150% reduction in common side effect compared to current treatment options.

Target:

GPR6 - an inverse agonist for parkinson’s disease

Study Focus:

GPR6 - an inverse agonist for parkinson’s disease

Highlight:

GPR6 - an inverse agonist for parkinson’s disease

Our approach differs radically from dopamine agonists currently being used and studied elsewhere to treat broad spectrum targets with highly undesirabl  e side effects.  CVN424 is an inverse agonist that targets GPR6, a novel gene we’ve identified using our NETSseq Platform.  GPR6 is highly selectively expressed in striatal medium spiny neurons only on the indirect pathway of the basal ganglia circuit. By targeting this essential mechanism Parkinson’s patients can experience significant improvements in disease “off time”, with significant reduction in adverse side effects compared to current dopaminergic treatment options.

Learn  more

Patient Resources:

We encourage connecting with organizations that focus on CNS diseases.   Below you’ll find learning opportunities, ideas on ways to care for and support those with diseases caused by CNS disorders as well as how to become a part of important research.